Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.
View Top Employees from ExscientiaWebsite | https://www.exscientia.ai |
Revenue | $33 million |
Funding | $568 million |
Employees | 497 (497 on RocketReach) |
Founded | 2012 |
Phone | +44 1865 818941 |
Industry | Biotechnology Research, Drug Manufacturing & Research, Artificial Intelligence, Drug Design, Pharmaceuticals, Data and Analytics, Bispecific Drugs, Healthcare, Science and Engineering, Polypharmacology, Software, Data Driven Drug Design, Biotechnology, Pharmaceutical, Health Care |
Web Rank | 6 Million |
Keywords | Drug Development And Manufacturing, Patient-Centric Healthcare, Oncology |
Competitors | Atomwise, BenevolentAI, QUEST PHARMA LIMITED, Text IQ, XtalPi Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular Exscientia employee's phone or email?
The Exscientia annual revenue was $33 million in 2024.
Garry Pairaudeau is the CTO of Exscientia.
497 people are employed at Exscientia.
The NAICS codes for Exscientia are [32, 325, 32541, 3254].
The SIC codes for Exscientia are [28, 283].